Calcitonin News and Research

RSS

Calcitonin is a 32-amino acid linear polypeptide hormone that is produced in humans primarily by the parafollicular cells (also known as C-cells) of the thyroid, and in many other animals in the ultimobranchial body.

New drug for migraine in the pipeline

According to a pilot study results released yesterday (17th of April 2018), a new drug may help provide relief to people with migraine that is unsuccessfully treated with the currently available drugs.

18 Apr 2018

New findings about fruit fly's body temperature rhythms may help people sleep better

In findings that one day may help people sleep better, scientists have uncovered the first molecular evidence that two anciently conserved proteins in the brains of insects and mammals share a common biological ancestry as regulators of body temperature rhythms crucial to metabolism and sleep.

13 Feb 2018

New drugs Erenumab and Fremanezumab show promise for migraine

Migraine headaches affect thousands of Americans and millions worldwide. There are several medications that are being prescribed for migraines and for many these do not work well.

30 Nov 2017

New immunotherapy study shows positive results in chronic migraine sufferers

A new study of fremanezumab, an immunotherapy that counteracts one of the molecules released during migraine, was found successful in reducing the number of days that chronic migraine sufferers experienced headaches.

30 Nov 2017

$Drug holiday from bisphosphonates for more than two years linked to higher hip fracture risk in women$

Drug holiday from bisphosphonates for more than two years linked to higher hip fracture risk in women

Women who took a drug holiday (temporary or permanent discontinuation of a medicine) from using bisphosphonates for more than two years have a significantly higher risk of a hip fracture compared to others who continued their treatment, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

New monoclonal antibody shows efficacy in chronic migraine patients with medication overuse

A new human antibody may soon become available as a specific medication for preventing frequent migraine attacks.

27 Jun 2017

Novartis announces data revealing efficacy of new monoclonal antibody therapy in preventing migraine

Novartis today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society.

8 Jun 2017

Cluster headaches: searching for effective therapies

Cluster headaches are probably the most painful types of pain a human can suffer and it is for no small reason that this condition is also sometimes referred to as suicide headache.

25 May 2017

PCT screening could be promising tool to help shorten hospital stays, reduce costs for sepsis patients

Each year, over $20 billion dollars is spent on sepsis care, making it the most expensive condition managed in U.S. hospitals.

10 Jan 2017

Scientists devise new radiation-free probe for imaging molecules in the brain

Scientists hoping to get a glimpse of molecules that control brain activity have devised a new probe that allows them to image these molecules without using any chemical or radioactive labels.

2 Dec 2016

New drug for chronic migraine may reduce headache hours in few days

A new drug to prevent migraine was associated with fewer headache hours for people with chronic migraine within three to seven days after the first injection, according to a study published in the June 8, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.

9 Jun 2016

Migraine drug has quick onset of action

The drug TEV-48125, shown to be effective for chronic migraine in a phase II trial, appears to work within 3 to 7 days of injection, researchers report.

9 Jun 2016

Additional drug treatment options to prevent migraine may offer hope to sufferers

Preventing or shortening the duration of migraine attacks - established drug treatment options and those that could shape future therapies were discussed at the Congress of European Academy of Neurology in Copenhagen.

1 Jun 2016

More phase II success for CGRP migraine prevention strategy

Another antibody targeting the calcitonin gene-related peptide pathway has proved successful against episodic migraine in a phase II trial.

18 Feb 2016

Oral formulation of insulin shows promise in management of blood glucose in diabetic rats

An intestinal patch device containing insulin that can be swallowed in the form of a capsule, in development by researchers at University of California Santa Barbara, has demonstrated efficacy of blood glucose management in diabetic rats. This work is being presented Oct. 27 at the 2015 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Orlando, Fla. Oct. 25-29.

28 Oct 2015

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics, Inc. today announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016.

19 Oct 2015

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

TEV-48125, a monoclonal anti-calcitonin-gene related peptide antibody, is well tolerated and effective in the prevention of high-frequency episodic migraine and chronic migraine, findings from two phase IIb studies show.

2 Oct 2015

EKF’s new Altair 240 revealed to UK audience at IBMS 2015

EKF, announces the UK launch of the Altair™ 240 clinical chemistry analyser at the Institute of Biomedical Science Congress 2015 in Birmingham.

From EKF Diagnostics 24 Sep 2015

MU researchers identify age-related cause of arterial dysfunction

With the world's elderly population expected to double by 2050, understanding how aging affects the body is an important focus for researchers globally. Cardiovascular disease, the No. 1 cause of death worldwide, often is associated with aging arteries that restrict blood flow. Now, University of Missouri researchers have identified an age-related cause of arterial dysfunction, a finding that could lead to future treatments for some forms of vascular disease.

9 Sep 2015

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration accelerates Amgen's potential entry into Alzheimer's disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer's disease program directed at genetically predisposed individuals at risk of developing Alzheimer's disease.

2 Sep 2015